IMU (ASX) Why IMU is a multi multi bagger

IMU

Click for more information

1.97%

7.8¢ imugene limited

First 21400 Last

Share
Profile

Follow
iluminaughty

2,441 Posts.

562

13/02/24

16:44

Post #: 72385870
Share

Originally posted by fattchoi: ↑

1. Vaxinia was extremely effective pre clinically.

So was every drug that ultimately proved non-commercial at Phase I, Phase II or Phase III human trials. Just ask CSL.

And so was every drug that ultimately proved commercial at PH1, PH2 or PH3.
Just ask Merck about their Keytruda which has expanded on its original indication far and wide by now.

2. Vaxinia’s inventor Professor Yuman Fong of the City of Hope Medical Research Facility in the US has a world renowned team of staff assisting him to improve upon and deliver his ground breaking research.

So does every drug that ultimately proved non-commercial at Phase I, Phase II or Phase III human trials.

And so do every drugs that were ultimately proved to be commercial at PH1, PH2 or PH3 human trials.

3. “In human” trials have resulted in disease stabilisation among late stage cancer patients at relatively low doses.

There has been 1 complete response out of 38 dosed patients, so it could have been the orange juice. This complete response was in a patient administered a relatively low dose. This is actually concerning. If it was a highly-dosed patient, the claim the higher doses would prove more efficacious would have more legs.

One complete response AND SEVERAL PARTIAL RESPONSE AND SEVERAL STABLE DISEASE. Definitely not orange juice here. It is actually concerning that you chose to ignore the rest. And fact is the Complete Response was on mid-dose. NO ifs or buts about that. No need to introduce uncertainty here when there is none so far.

4. Despite the innumerable number of treatment arms espousing to tackle and target the burgeoning solid tumour market, as of yet there is no mainstream standard of care, outside of chemotherapy and existing immunotherapies (i.e, Mab’s). Aside from providing the silver bullet required to tackle solid tumours, although being responsible for a slight increase in life expectancy, many existing therapies have done so at the expense of extraneous side effects.“Could those suggesting Vaxinia may fail, that IMU is worth 6 cents, that the stock is a shorter’s paradise, a meme stock, please come forth…’ WMHB February 12, 2024

Present sir. Vaxinia may fail. If it does, 6c won't hold. The stock has been a shorter's paradise. And why wouldn't it be? The chairman sold at 45c and lent over 100m shares to shorters. Can you find one other chairman on the ASX that acted in this manner?

And if Vaxinia succeed, then $6 won't be enough. Maybe even $60 might not be enough. This is why IMU is such a LOW RISK, VERY HIGH REWARD play considering the potential upside vs the downside from here at 10 cents. If it fails and falls to 1 cents, you are down by 90%. If it should reach $1, you are up 1000%. And if it were to hit $5 (very easily should they get a cure for just one type of solid cancer), then you would be up 5000%. At end of day, the most you can lose from here is about 10 cents/share but the gains is potentially the sky is the limit

Expand

IMU Price at posting: 10.5¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 1,881 more messages in this thread...

First 21400 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 7.8¢		Change 0.002(1.97%)		Mkt cap ! $556.3M

Open	High	Low	Value	Volume
7.7¢	7.8¢	7.5¢	$783.2K	10.26M

Buyers (Bids)

No.	Vol.	Price($)
18	501151	7.7¢

Sellers (Offers)

Price($)	Vol.	No.
7.8¢	1185254	25

View Market Depth

No.	Vol.	Price($)
20	563372	0.077
25	1262867	0.076
26	1496625	0.075
14	777997	0.074
17	1225831	0.073

Price($)	Vol.	No.
0.078	1193748	25
0.079	1333744	13
0.080	433309	11
0.081	32348	2
0.082	490759	7

Last trade - 12.43pm 08/05/2024 (20 minute delay)


Last 7.8¢		Change 0.002 ( 2.63 %)
Open	High	Low	Volume
7.6¢	7.8¢	7.5¢	4595464
Last updated 13.03pm 08/05/2024 ?

IMU (ASX) Chart

Featured News

Alara Resources (ASX:AUQ) is driving Oman into a renewable renaissance with accelerating copper production

Gold grading beyond 65g/t at Hillgrove gets Larvotto shares airborne

Maiden drilling at West Arunta hints at major IOCG system for Rincon

Mantle Minerals to kick off drilling at Mt Berghaus in WA

Tamboran is listing on the NYSE, and Wall Street is paying attention

Buyers (Bids)

Sellers (Offers)

Featured News

Featured News

Top Stories

Alara Resources (ASX:AUQ) is driving Oman into a renewable renaissance with accelerating copper production

Gold grading beyond 65g/t at Hillgrove gets Larvotto shares airborne

Maiden drilling at West Arunta hints at major IOCG system for Rincon

Mantle Minerals to kick off drilling at Mt Berghaus in WA

Tamboran is listing on the NYSE, and Wall Street is paying attention

Buyers (Bids)

Sellers (Offers)

Featured News